隨著全球人口老齡化與慢性病增加，加上COVID-19疫情推動遠距醫療與個人化健康管理的需求，數位醫療裝置市場呈現高速成長趨勢。然而，醫療器材產品逐漸商品化，導致市場競爭加劇，業者面臨產品差異性降低、毛利壓縮的壓力。如何透過科技創新與數位能力提升產品附加價值與客戶忠誠度，已成為醫療科技產業的重要課題。
本研究以全球知名的M醫學科技公司為研究對象，透過PESTEL模型、波特五力分析、SWOT與TOWS矩陣、安索夫矩陣及商業模式九宮格等策略分析工具，深入探討其數位醫療裝置市場應用情境與商業模式。
研究發現，M公司憑藉強大的研發創新能力、全面的臨床驗證與全球化布局，已在血壓監測與體溫量測等領域建立了卓越品牌形象與競爭優勢。該公司積極透過與臨床研究機構(CRO)、社區藥局等多元通路合作，並持續進行產品創新與數位化轉型，滿足市場對高品質與智慧化健康管理需求。
然而，M公司亦面臨新興技術競爭者快速崛起、國際貿易政策不確定性、數位數據安全議題等挑戰。針對未來發展，本研究建議M公司應積極布局穿戴式裝置與AI數據分析平台，深化專業級產品線布局，持續強化品牌價值與臨床實證基礎，並透過製造外包與彈性供應鏈策略，有效分散經營風險。
透過深入的分析與策略建議，本研究期望能提供數位醫療裝置產業具體實務參考，並協助業界廠商掌握市場變動機會，維持長期競爭力。

Driven by global population aging, the rise of chronic diseases, and the COVID-19 pandemic, the digital medical device market is experiencing rapid growth due to increased demand for telemedicine and personalized health management. However, medical devices are becoming commoditized, intensifying market competition, leading to reduced product differentiation and margin pressures. Leveraging technological innovation and digital capabilities to enhance product value and customer loyalty has thus become critical in the medical technology industry.
This research analyzes the market application scenarios and business models of digital medical devices by studying the globally renowned M Medical Technology Company. Utilizing strategic analysis tools such as the PESTEL model, Porter’s Five Forces, SWOT and TOWS matrices, Ansoff matrix, and the Business Model Canvas, this study deeply investigates the strategies employed by M Company.
Findings reveal that M Company has built an exceptional brand reputation and competitive advantages in areas like blood pressure and temperature monitoring, thanks to its robust innovation capabilities, comprehensive clinical validations, and global market presence. The company proactively collaborates with Clinical Research Organizations (CROs), community pharmacies, and other diverse channels, continuously innovating products and undertaking digital transformation to meet high-quality and intelligent health management demands.
However, M Company faces challenges such as rapid emergence of new technology competitors, uncertainties in international trade policies, and digital data security concerns. To address these, the study recommends M Company proactively expand into wearable devices and AI data analysis platforms, deepen professional product lines, reinforce brand value and clinical evidence base, and effectively mitigate operational risks through manufacturing outsourcing and flexible supply chain strategies.
Through detailed analysis and strategic recommendations, this research aims to provide practical guidance for the digital medical device industry, helping businesses capitalize on market dynamics and maintain long-term competitiveness.

一、 中文書籍及論文
麥可.波特(Michael Porter)著，周旭華譯(第四版2019)；競爭策略: 產業環境及競爭者分析，圖1.1產業競爭的五股作用力，頁34。
亞歷山大.奧斯瓦爾德(Alexander Osterwalder)、伊夫.比紐赫(Yves Pigneur)著，尤傳莉譯(初版2012)；獲利世代 Business Model Generation，頁44。
二、 期刊書籍
邱璟綾(2024)。生醫健康邁入智慧醫療時代。《工業技術與資訊》，391，30–32頁。
工業技術研究院，吳信茂(2024) 。新科技.創未來，2024年智慧醫療產業之關鍵趨勢與未來展望
三、 法規引用
U.S. Congress. (1976). Medical Device Amendments of 1976, Public Law No. 94-295. Retrieved from https://www.fda.gov/about-fda/fda-basics/medical-device-amendments-1976
U.S. Food and Drug Administration. (1989). FDA policy for the regulation of computer products. Retrieved from https://www.fda.gov/media/73194/download
U.S. Food and Drug Administration. (2005). General principles of software validation: Final guidance for industry and FDA staff. Retrieved from https://www.fda.gov/media/73141/download
U.S. Food and Drug Administration. (2013). Mobile medical applications: Guidance for industry and FDA staff. Retrieved from https://www.fda.gov/media/80958/download
U.S. Congress. (2016). 21st Century Cures Act, Public Law No. 114-255. Retrieved from https://www.congress.gov/bill/114th-congress/house-bill/34
U.S. Food and Drug Administration. (2017). Digital health innovation action plan. Retrieved from https://www.fda.gov/media/106331/download
U.S. Food and Drug Administration. (2019). Device software functions including mobile medical applications: Guidance for industry and FDA staff. Retrieved from https://www.fda.gov/media/80958/download
U.S. Food and Drug Administration. (2020). About the Digital Health Center of Excellence. Retrieved from https://www.fda.gov/medical-devices/digital-health-center-excellence
U.S. Food and Drug Administration. (2023). Digital health technologies for remote data acquisition in clinical investigations. Retrieved from https://www.fda.gov/media/155022/download
四、 網路文章
World Health Organization. (2010). Medical devices: managing the mismatch: an outcome of the Priority Medical Devices project. WHO Press.
U.S. Food & Drug Administration (FDA). (2021). Digital Health. Retrieved from https://www.fda.gov/medical-devices/digital-health-center-excellence
GlobalData. (2022). IoT in Healthcare. Retrieved from https://www.globaldata.com
Deloitte. (2023). Intelligent Health Report: The future of AI in healthcare. Retrieved from https://www.deloitte.com
Precedence Research. (2024). Blood Pressure Monitoring Devices Market. Retrieved from
https://www.precedenceresearch.com/blood-pressure-monitoring-devices-market
IQVIA Institute. (2024). Digital Health Trends 2024: Implications for Research and Patient Care. Retrieved from https://www.iqviainstitute.org
Increasing blood pressure checks in community pharmacy: cardiovascular disease impact(2023)
https://www.gov.uk/government/publications/increasing-blood-pressure-checks-in-community-pharmacy-cardiovascular-disease-impact/increasing-blood-pressure-checks-in-community-pharmacy-cardiovascular-disease-impact
Service toolkit: Blood pressure checks(2023)
https://www.pharmacymagazine.co.uk/clinical/service-toolkit-blood-pressure-checks
WHO The Global Health Observatory Explore a world of health data
https://www.who.int/data/gho/data/indicators/indicator-details/GHO/gho-ghe-hale-healthy-life-expectancy-at-birth